Dendritic cells in vaccination therapies of malignant diseases
- 31 October 2002
- journal article
- review article
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 27 (2) , 183-186
- https://doi.org/10.1016/s1473-0502(02)00041-1
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Synthetic insertion signal sequences enhance MHC class I presentation of a peptide from the melanoma antigen MART-1European Journal of Immunology, 2000
- Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNANature Biotechnology, 1998
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998
- Origin, maturation and antigen presenting function of dendritic cellsCurrent Opinion in Immunology, 1997
- Generation of mature dendritic cells from human blood An improved method with special regard to clinical applicabilityJournal of Immunological Methods, 1996
- Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.The Journal of Experimental Medicine, 1996
- Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cellsNature Medicine, 1996
- Autologous cytolytic T lymphocytes recognize a MAGE‐1 nonapeptide on melanomas expressing HLA‐Cw* 1601European Journal of Immunology, 1994
- Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytesEuropean Journal of Immunology, 1994
- Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.The Journal of Experimental Medicine, 1994